Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors

Mise à jour : Il y a 4 ans
Référence : NCT01148628

Femme et Homme

Extrait

This is a dose finding, open-label, uncontrolled, dose-escalation trial to determine the Maximum Tolerated Dose (MTD) and the Recommended Dose (RD) of the combination RAD001 (escalating daily dose) and CaelyxTM (fixed dose) to patients with advanced solid tumors. Other purposes of the study are: 1. define the safety profile of the combination after repeated administrations 2. define hints of antitumor activity, to be confirmed in subsequent disease-oriented expansion phases at the RD. 3. define the pharmacokinetic profile of the combination


Critère d'inclusion

  • Advanced solid tumors

Liens